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Mesothelioma is a rare tumour arising from the serosal surfaces of the pleura, peritoneum and
other body cavity linings. Distant cutaneous metastases of mesothelioma are rarely noted but
have been previously reported. This case demonstrates both cutaneous and soft tissue metas-
tases to the kidney, lung, thyroid, lymph nodes and tongue from a pleural malignant mesothe-
lioma. These metastases were demonstrated during the lifetime of the patient, most are noted
post-mortem. To the best of our knowledge, this distribution of both cutaneous and soft tissue
metastases has not previously been reported. We propose that as the incidence of mesothe-
lioma increases and life expectancy is altered by treatment, metastases may be a more
common occurrence.
ª 2008 Elsevier Ltd. All rights reserved.Case report
A 54-year-old man with a 30-pack year history of smoking with
no recalledhistoryofasbestos exposurepresentedwithweight
loss and no respiratory symptoms. A chest X-ray showed) 7904044523.
ctors.net.uk (S.V. Fletcher).
ll rights reserved.extensive pleural thickening around the left lung. A CT (com-
puterised tomography) scan noted an extensive pleural-based
tumour encasing the left lung. There was also mediastinal
adenopathy, lung nodules and invasion of the ribs. A CT guided
biopsy of the pleural tumour was undertaken.
Biopsies showed an infiltrative biphasic tumour having
both a spindle celled and epithelioid pattern. Immunocy-
tochemistry showed both components to be strongly posi-
tive for calretinin, BerEp4 and CEA with occasional cells
26 S.V. Fletcher et al.showing weak staining for CK5/6. No mucin was identified
within the tumour cells. This pattern of immunoreactivity is
consistent with malignant mesothelioma.
The patient received 5 months of palliative chemo-
therapy (pemetrexed and cisplatin). Three months
following completion of the course treatment he noted
a soft tissue swelling on the scalp; initially thought to be
a sebaceous cyst, it was excised under local anaesthetic by
his general practitioner. Microscopy of the skin specimen
showed bands of epithelioid cells infiltrating a fibrous
stroma. Immunocytochemistry demonstrated tumour cells
to be positive for calretinin and CK5/6. The pattern of
immunoreactivity was consistent with mesothelioma, con-
firming that the skin lesion was a metastasis.
The following month a neck swelling was noted by the
patient. A second CT showed significant lymphadenopathy
at the base of the neck extending to the axilla and supra-
clavicular fossae. There were also multiple pulmonary
metastases in the right lung that had increased both in size
and number, multiple enlarged nodes in the upper
abdomen, multiple gluteal subcutaneous deposits and a low
attenuation lesion in the left kidney consistent with
a metastasis. There was also a mass in the thyroid extending
to the isthmus and an abnormal focus in the tongue. A core
biopsy was undertaken of thyroid, this biopsy consisted of
tumour cells surrounded thyroid follicles. These tumour
cells were positive for calretinin, BerEp4, weakly positive
for CK5/6 and negative for thyroglobulin. This pattern of
immunoreactivity is consistent with metastatic mesothe-
lioma infiltrating the thyroid gland.
Discussion
Malignant mesothelioma is an uncommon tumour and skin
metastases are rare, skin involvement is usually secondary
to direct tumour spread1,2 or contamination of surgical
sites.3 Widespread cutaneous metastases4 and metastases
to the tongue,5 brain6 and lymph nodes7 have previously
been reported. This case demonstrates both widespread
cutaneous and soft tissue including thyroid, metastases.
Mesothelioma is traditionally thought of as a primary
tumour that rarely metastases, this case report adds to
growing evidence to support that this is not a universal truth
and the tumour is capable of spreading to a variety of sites.
Reported cases of symptomatic mesothelioma metastases
remain rare and most are noted post-mortem. This case
demonstrates histologically the presence of metastases
ante-mortem in two separate sites, and in the case of the
thyroid, a site not previously reported.
The majority of patients with mesothelioma present at
an advanced stage. The optimum local and/or systemictreatment is yet to be defined and prognosis remains poor.
A combination of cisplatin and pemetrexed has shown an
increase in median survival,8 we propose that this may
effect a change in the natural history of the disease. This is
further supported by findings from thoracic surgical studies
where metastatic mesothelioma can become the predomi-
nant pattern of failure following aggressive surgical
resection.9
We postulate that treatment with chemotherapy
allowed time for metastases to occur in the context of
a primary tumour that otherwise would rarely metastasise
due to an extremely poor prognosis. Perhaps in the context
of radical surgical and systemic treatments mesothelioma
should no longer be considered as a progressive primary
tumour alone. This report adds to the documented sites of
potential metastasis.
Conflict of interest Statement
There are no conflicts of interests for any of the authors, to
declare.
References
1. Ordenez NG, Smith LS. Peritoneal malignant mesothelioma
with multiple skin metastases. Arch Dermatol 1983;119:
826.
2. Maiorana A, Giusti F, Cesinaro AM, Conti A, Rossi G. Cutaneous
metastases as the first manifestation of pleural malignant
disease. J Am Acad Dermatol 2006;54:363e5.
3. Shieh S, Grassi M, Schwartz JK, Cheney RT. Pleural mesothe-
lioma with cutaneous extension to chest wall scars. J Cutan
Pathol 2004;31:497e501.
4. Cassariono DS, Xue W, Shannon KJ. Widespread cutaneous and
perioral metastases of mesothelioma. J Cutan Pathol 2003;30:
582e5.
5. Piattelli A, Fioroni M, Rubini C. Tongue metastases from
a malignant diffuse mesothelioma of the pleura: report of
a case. J Oral Maxillofac Surg 1999;57:861e3.
6. Mah E, Bittar RG, Davis GA. Cerebral metastases in malignant
mesothelioma: case report and literature review. J Clin Neu-
rosci 2004;11:917e8.
7. King JA, Listinsky CM, Tucker JA. An intriguing case: malignant
mesothelioma presenting as inguinal lymph node metastases.
Ultrastruct Pathol 2004;28:109e13.
8. Manegold C, Symanowski J, Gatzemeier U, et al. Second line
(post-study) chemotherapy received by patients in the
phase III trail of pemetrexed plus cisplatin versus cisplatin
alone in malignant pleural mesothelioma. Ann Oncol 2005;16:
923e7.
9. Janne PA, Baldini EH. Patterns of failure following surgical
resection for malignant pleural mesothelioma. Thorac Surg Clin
2004;14:567e73.
